AlMehdi, S., Al Zubaidi, A. (2024). Patients profile, pattern of presentation and response rate to first line chemotherapy in Iraqi patients with extensive stage small cell lung cancer. , 23(4), 386-391. doi: 10.52573/ipmj.2024.138632
Samar AlMehdi; Azher Al Zubaidi. "Patients profile, pattern of presentation and response rate to first line chemotherapy in Iraqi patients with extensive stage small cell lung cancer". , 23, 4, 2024, 386-391. doi: 10.52573/ipmj.2024.138632
AlMehdi, S., Al Zubaidi, A. (2024). 'Patients profile, pattern of presentation and response rate to first line chemotherapy in Iraqi patients with extensive stage small cell lung cancer', , 23(4), pp. 386-391. doi: 10.52573/ipmj.2024.138632
AlMehdi, S., Al Zubaidi, A. Patients profile, pattern of presentation and response rate to first line chemotherapy in Iraqi patients with extensive stage small cell lung cancer. , 2024; 23(4): 386-391. doi: 10.52573/ipmj.2024.138632

Patients profile, pattern of presentation and response rate to first line chemotherapy in Iraqi patients with extensive stage small cell lung cancer

Iraqi Postgraduate Medical Journal
Article 2, Volume 23, Issue 4, October 2024, Pages 386-391    PDF (297.72 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2024.138632
Authors
Samar AlMehdi* 1; Azher Al Zubaidi2
1Department of Oncology, Baghdad Oncology Teaching Hospital, Medical City
2Department of Oncology, College of Medicine, University of Baghdad
Abstract
Background: Lung cancer is the leading cause of cancer death worldwide, it comprises small cell and non-small cell subtypes. Small cell lung cancer carries a poorer prognosis, and it is mainly caused by cigarette smoking.
Objectives: To assess response rate of extensive stage small cell lung cancer to first line chemotherapy and assess patient profile with pattern of presentation in Iraqi patients.
Method: A cross-sectional study for small cell lung cancer patients who were treated at oncology teaching hospital, from January 1st 2020 to September 30th 2020 and included 30 patients with extensive stage small cell lung cancer.
Results: Sixty patients with small cell lung cancer were interviewed, 30 patients of them were included in this study. The mean age of the patients was 58.27±9.71years. Males represented more than three quarters of the patients (76.67%). The male female ratio was 1:0.3. The mean weight, height and body mass index of the patients were 67.2±12.52 kg, 168.93±8.8 cm and 23.48±3.58 kg/m2, respectively. Almost all patients were either ex-smokers or current smokers. Cough was the most common presentation encountered in 11 patients (36.67%). Eight patients (26.67%) showed no response to the treatment, while 22 patients (73.3%) had clinical benefit of which 10 patients (33.33%) were stable, 10 patients (33.33%) had partial response and two patients (6.67%) had complete remission. Mean progression free survival time was 6.71±1.5 months, 95%CI= 5.83-7.6. After three months, in 8 patients (26.67%) the disease progressed, while almost all other patients had progression free survival till 7-9 months after treatment.
Conclusion: Extensive stage small cell lung cancer is an aggressive disease that is chemosensitive but rapidly progressive in Iraqi patients. It is adherent to tobacco exposure with male to female ratio of 1:0.3. Affected population is mostly middle age group, presenting with cough.
Keywords
Small Cell Lung Cancer,,; ,،,؛Extensive Stage,,; ,،,؛Response Rate
References
  1. Oei L, Rivadeneira F, Zillikens MC, Oei EHG. Diabetes, diabetic complications, and fracture risk. Curr Osteoporos Rep. 2015;13:106–15.
  2. Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016;27:219–28.
  3. Shah VN, Shah CS, Pharm M, Snell-Bergeon JK. Type 1 diabetes and risk for fracture: meta-analysis and review of the literature. Diabet Med. 2015;32:1134–42.
  4. Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture. Diabetes Care. 2006;29:1573–78.
  5. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women’s health initiative observational study. J Clin Endocrinol Metabol 2006;91:3404–10.
  6. Botella-Martínez S, Varo Cenarruzabeitia N, Escalada San Martin J, et al. The diabetic paradox: Bone mineral density and fracture in type 2 diabetes. Endocrinol Nutr. 2016;63:495–501.
  7. Kim J, Kim E, Lee B, , et al: The effects of Lycii Radicis Cortex on RANKL-induced osteoclast differentiation and activation in RAW 264.7 cells. Int J Mol Med , 201;37: 649-58.
  8. Oei L, Zillikens MC, Dehghan A, et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: The Rotterdam Study. Diabetes Care. 2013;36:1619-28.
  9. Meier C, Schwartz AV, Egger A, et al. Effects of diabetes drugs on the skeleton. Bone. 2016;82:93-100.
  10. Bilezikian JP, Josse RG, Eastell R, et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98:1519-28.
  11. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8-10.
  12. Carey JJ, Delaney MF. T-Scores and Z-Scores. Clinic Rev Bone Miner Metab 2010;8:113–21.
  13. Loxton P, Narayan K, Munns CF, Craig ME. Bone Mineral Density and Type 1 Diabetes in Children and Adolescents: A Meta-analysis. Diabetes Care. 2021;44:1898-905.
  14. Mastrandrea LD, Wactawski-Wende J, Donahue RP, et al. Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care. 2008;31:1729-35.
  15. Asokan AG, Jaganathan J, Philip R, et al. Evaluation of bone mineral density among type 2 diabetes mellitus patients in South Karnataka. J Nat Sc Biol Med 2017;8:94-98.
  16. Tuominen JT, Impivaara O, Puukka P, et al. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care. 1999;22:1196-200.
  17. Wakasugi M, Wakao R, Tawata M, Gan N, et al. Bone mineral density by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 1193;14:29–33.
  18. Sosa M, Dominquez M, Navarro MC, Segarra MC, et al. Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complications 1996 ;10:201-5.
  19. Vestergaard, “Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a metaanalysis,” Osteoporosis Int 2007; 18: 427–44.
  20. Strotmeyer and J. Cauler, “Diabetes mellitus, bone mineral density, and fracture risk,” Curr Opinion in Endocrinol Diabetes Obesity 2007;14:429–35.
  21. Bilha SC, Leustean L, Preda C, et al. Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus. BMC Endocr Disord 2021; 21,156.
  22. Sauque-Reyna L, Salcedo-Parra MA, Sánchez-Vargas PR, et al. Densidad mineral ósea en pacientes con diabetes tipo 2. Rev Invest Clin. 2011;63:162-69.
  23. de Liefde I, van der Klift M, de Laet CE, et al. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005;16:1713-20.
  24. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: The role of PPAR-gamma2transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. 2004;3: 379–89. 
  25. Botolin S, McCabe LR. Inhibition of PPAR-Gamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol. 2006;209:967–76. 
  26. Bazelier MT, de Vries F, Vestergaard P, Herings RM, Gallagher AM, Leufkens HG, et al. Risk of fracture with thiazolidinediones: An individual patient data meta-analysis. Front Endocrinol (Lausanne) 2013;4:11. 
  27. Coe LM, Irwin R, Lippner D, McCabe LR. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol. 2011;226:477–83.
  28. Fraser JH, Helfrich MH, Wallace HM, Ralston SH. Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone. 1996;19:223–26.
  29. Suzuki K, Miyakoshi N, Tsuchida T, et al. Effects of combined treatment of insulin and human parathyroid hormone (1–34) on cancellous bone mass and structure in streptozotocin induced diabetic rats. Bone 2003;33:108-14.
 

 

 

Statistics
Article View: 302
PDF Download: 137


Journal Management System. Powered by iJournalPro.com